Skip to main content

Qiagen, Geneart to Sell Synthetic Genes for Protein Production

NEW YORK (GenomeWeb News) – Qiagen and German gene synthesis company Geneart announced today that they are collaborating to commercialize a set of plasmids containing synthetic genes representing the entire human genome.
 
The QIAgenes plasmids will allow researchers to produce large quantities of some 35,000 human proteins. The product stems from a joint research and development project between Qiagen and Geneart, wherein Geneart contributed plasmid and gene synthesis technology and Qiagen supplied automated protein purification technology.
 
According to Qiagen, validation experiments done on 100 proteins indicate that the QIAgenes have success rates exceeding 90 percent and yield 50 times more protein than conventional methods, resulting from optimized synthetic genes and purification methods.
 
“In the past, researchers faced a multiple bottleneck situation when producing protein in sufficient quantity and quality for their research,” Kai te Kaat, Qiagen's global business director for proteins, said in a statement. “With the new QIAgenes product portfolio … our customers can now access the human proteome with a simple mouse click and significantly increase their successes expressing and purifying their protein of choice.”

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.